BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14692533)

  • 1. Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma.
    Li ZH; Wen XY; Mandelbaum S; Falcioni N; Hawley TS; Hawley RG; Stewart AK
    Leuk Lymphoma; 2003 Oct; 44(10):1775-84. PubMed ID: 14692533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stripecke R; Skelton DC; Pattengale PK; Shimada H; Kohn DB
    Hum Gene Ther; 1999 Sep; 10(13):2109-22. PubMed ID: 10498243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
    Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
    Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action.
    Braun SE; Chen K; Blazar BR; Orchard PJ; Sledge G; Robertson MJ; Broxmeyer HE; Cornetta K
    Hum Gene Ther; 1999 Sep; 10(13):2141-51. PubMed ID: 10498246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
    Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
    Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
    Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
    Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.
    Parney IF; Petruk KC; Zhang C; Farr-Jones M; Sykes DB; Chang LJ
    Hum Gene Ther; 1997 Jun; 8(9):1073-85. PubMed ID: 9189765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
    Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Gruber TA; Skelton DC; Kohn DB
    J Immunol; 2002 Jan; 168(1):73-80. PubMed ID: 11751948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens.
    Hsieh CL; Pang VF; Chen DS; Hwang LH
    Hum Gene Ther; 1997 Nov; 8(16):1843-54. PubMed ID: 9382951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes.
    Shtil AA; Turner JG; Durfee J; Dalton WS; Yu H
    Blood; 1999 Mar; 93(6):1831-7. PubMed ID: 10068654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
    Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
    Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.